BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35320921)

  • 41. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy.
    Huang Z; Li Z; Wang J; Gui R; Zu Y; Yu F; Lin Q; Zhao H; Zhang Y; Fang B; Liu Y; Zhou K; Li Y; Fu Y; Yao Z; Song Y; Zhou J
    Front Oncol; 2023; 13():1162413. PubMed ID: 37256185
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
    Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
    Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group.
    Rodríguez J; Conde E; Gutiérrez A; Arranz R; León A; Marín J; Bendandi M; Albo C; Caballero MD;
    Eur J Haematol; 2007 Jul; 79(1):32-8. PubMed ID: 17598836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
    Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
    Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
    Sweetenham JW; Santini G; Qian W; Guelfi M; Schmitz N; Simnett S; Nagler A; Holte H; Kvaloy S; Bruzzi P; Goldstone AH
    J Clin Oncol; 2001 Jun; 19(11):2927-36. PubMed ID: 11387366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Stem cell transplantation for peripheral T-cell lymphomas.
    Jantunen E; D'Amore F
    Leuk Lymphoma; 2004 Mar; 45(3):441-6. PubMed ID: 15160904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
    Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
    Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
    Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study.
    Chin CK; Lim KJ; Lewis K; Jain P; Qing Y; Feng L; Cheah CY; Seymour JF; Ritchie D; Burbury K; Tam CS; Fowler NH; Fayad LE; Westin JR; Neelapu SS; Hagemeister FB; Samaniego F; Flowers CR; Nastoupil LJ; Dickinson MJ
    Br J Haematol; 2020 Dec; 191(5):806-815. PubMed ID: 33065767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?
    Casulo C; Horwitz S
    Curr Oncol Rep; 2010 Nov; 12(6):374-82. PubMed ID: 20737300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
    Lunning MA; Horwitz S
    Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
    DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
    Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.
    Jantunen E; Wiklund T; Juvonen E; Putkonen M; Lehtinen T; Kuittinen O; Franssila K; Söderström KO; Leppä S; Elonen E; Remes K; Nousiainen T
    Bone Marrow Transplant; 2004 Feb; 33(4):405-10. PubMed ID: 14676776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
    Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.
    Corradini P; Tarella C; Zallio F; Dodero A; Zanni M; Valagussa P; Gianni AM; Rambaldi A; Barbui T; Cortelazzo S
    Leukemia; 2006 Sep; 20(9):1533-8. PubMed ID: 16871285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
    Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
    Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.